Your browser doesn't support javascript.
loading
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays.
Mühlemann, Barbara; Wilks, Samuel H; Baracco, Lauren; Bekliz, Meriem; Carreño, Juan Manuel; Corman, Victor M; Davis-Gardner, Meredith E; Dejnirattisai, Wanwisa; Diamond, Michael S; Douek, Daniel C; Drosten, Christian; Eckerle, Isabella; Edara, Venkata-Viswanadh; Ellis, Madison; Fouchier, Ron A M; Frieman, Matthew; Godbole, Sucheta; Haagmans, Bart; Halfmann, Peter J; Henry, Amy R; Jones, Terry C; Katzelnick, Leah C; Kawaoka, Yoshihiro; Kimpel, Janine; Krammer, Florian; Lai, Lilin; Liu, Chang; Lusvarghi, Sabrina; Meyer, Benjamin; Mongkolsapaya, Juthathip; Montefiori, David C; Mykytyn, Anna; Netzl, Antonia; Pollett, Simon; Rössler, Annika; Screaton, Gavin R; Shen, Xiaoying; Sigal, Alex; Simon, Viviana; Subramanian, Rahul; Supasa, Piyada; Suthar, Mehul S; Türeli, Sina; Wang, Wei; Weiss, Carol D; Smith, Derek J.
Afiliação
  • Mühlemann B; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Wilks SH; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Baracco L; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Bekliz M; Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Carreño JM; Department of Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
  • Corman VM; Centre for Emerging Viral Diseases, University Hospitals of Geneva and University of Geneva, CH-1211, Geneva, Switzerland.
  • Davis-Gardner ME; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Dejnirattisai W; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Diamond MS; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Douek DC; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Drosten C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Eckerle I; Division of Emerging Infectious Disease, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok 10700, Thailand.
  • Edara VV; Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Ellis M; Andrew M. and Jane M. Bursky the Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Fouchier RAM; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Frieman M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Godbole S; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Haagmans B; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Halfmann PJ; Department of Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
  • Henry AR; Centre for Emerging Viral Diseases, University Hospitals of Geneva and University of Geneva, CH-1211, Geneva, Switzerland.
  • Jones TC; Division of Infectious Diseases, Geneva University Hospitals, CH-1211 Geneva, Switzerland.
  • Katzelnick LC; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Kawaoka Y; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Kimpel J; Viroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.
  • Krammer F; Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Lai L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Liu C; Viroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.
  • Lusvarghi S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
  • Meyer B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mongkolsapaya J; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Montefiori DC; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Mykytyn A; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Netzl A; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pollett S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
  • Rössler A; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Screaton GR; Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Shen X; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo 162-8655, Japan.
  • Sigal A; Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria.
  • Simon V; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Subramanian R; Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Supasa P; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Suthar MS; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Türeli S; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Wang W; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford OX3 7BN, UK.
  • Weiss CD; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Smith DJ; Centre of Vaccinology, Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva, Switzerland.
Sci Transl Med ; 16(747): eadl1722, 2024 May 15.
Article em En | MEDLINE | ID: mdl-38748773
ABSTRACT
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires ongoing monitoring to judge the ability of newly arising variants to escape the immune response. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal serum samples. We compared 18 datasets generated using human, hamster, and mouse serum and six different neutralization assays. Datasets using animal model serum samples showed higher titer magnitudes than datasets using human serum samples in this comparison. Fold change in neutralization of variants compared to ancestral SARS-CoV-2, immunodominance patterns, and antigenic maps were similar among serum samples and assays. Most assays yielded consistent results, except for differences in fold change in cytopathic effect assays. Hamster serum samples were a consistent surrogate for human first-infection serum samples. These results inform the transition of surveillance of SARS-CoV-2 antigenic variation from dependence on human first-infection serum samples to the utilization of serum samples from animal models.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Neutralização / Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Neutralização / Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article